Announcement on Full Subsidiary's Innovative Drug APH04935 Obtaining Clinical Trial Approval Notice

ApicHope Pharmaceutical Group Co., Ltd.·August 17, 2026·2 pages

✨ AI Summary

Guangzhou Yipinhong Pharmaceutical's innovative drug APH04935 has received clinical trial approval from China's NMPA for weight control. This small molecule GLP-1R agonist aims for once-daily oral administration. While approval is a positive step, the company notes that drug development is high-risk and the impact on future performance is uncertain.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300723

Stock Abbreviation: Yipinhong

Announcement No.: 2026-050

Yipinhong Pharmaceutical Group Co., Ltd.

Announcement on Full Subsidiary's Innovative Drug APH04935 Obtaining Clinical Trial Approval Notice

The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and are free from any false representations, misleading statements, or material omissions.

Recently, Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yipinhong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), has obtained approval from the National Medical Products Administration for its innovative drug APH04935, and has received the "Drug Clinical Trial Approval Notice," and will commence clinical trials soon. The relevant situation is hereby announced as follows:

I. Main Content of the "Drug Clinical Trial Approval Notice"

Drug Name	Application Item	Indication	Acceptance Number
APH04935	Domestic Drug Registration	For weight control	CXHL2600660
	Clinical Trial		CXHL2600661
			CXHL2600662

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.